MedTrace Logo

Effect of F. Prausnitzii on Glycemic Control

NCT04938843 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2021-09-02

No results posted yet for this study

Summary

The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F. prausnitzii, which is a part of the human gut microbiota, can improve metabolic parameters in subjects with impaired glucose control.

Conditions

  • Pre Diabetes
  • Impaired Glucose Tolerance
  • Non-Alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

F. prausnitzii and D. piger

Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks

DIETARY_SUPPLEMENT

Placebo

Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks

Sponsors & Collaborators

  • Göteborg University

    collaborator OTHER

  • MetaboGen AB

    lead INDUSTRY

Principal Investigators

  • Hanns-Ulrich Marschall · Wallenberg Laborotory, University of Gothenburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938843 on ClinicalTrials.gov